Literature DB >> 18085527

Choroid plexus cyst, intracardiac echogenic focus, hyperechogenic bowel and hydronephrosis in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.

T Dagklis1, W Plasencia, N Maiz, L Duarte, K H Nicolaides.   

Abstract

OBJECTIVES: To investigate the potential value of choroid plexus cyst, intracardiac echogenic focus, hydronephrosis and hyperechogenic bowel as markers of trisomy 21 at 11 + 0 to 13 + 6 weeks.
METHODS: We examined three-dimensional volumes from 228 fetuses with trisomy 21 and 797 chromosomally normal fetuses at 11 + 0 to 13 + 6 weeks of gestation. We looked for choroid plexus cysts with a minimum diameter of 1.5 mm, intracardiac echogenic focus, hydronephrosis with a minimum anteroposterior diameter of the pelvis of 1.5 mm and hyperechogenic bowel.
RESULTS: The prevalence of intracardiac echogenic focus, hydronephrosis and hyperechogenic bowel was significantly higher in trisomy 21 than in normal fetuses (9.6% vs. 1.5%, 17.1% vs. 5.3% and 11.4% vs. 2.4%, respectively). There was no significant difference between the two groups in the prevalence of choroid plexus cysts (7.5% vs. 5.0%). There were no significant differences in crown-rump length or nuchal translucency thickness in either chromosomally normal or trisomy 21 fetuses between those with and those without any one of the markers.
CONCLUSIONS: At 11 + 0 to 13 + 6 weeks the prevalence of intracardiac echogenic focus, hydronephrosis and hyperechogenic bowel is higher in trisomy 21 than in chromosomally normal fetuses. As there is no significant association between the presence of these markers and nuchal translucency thickness, they could be included in the assessment of risk to improve accuracy of screening. Copyright (c) 2007 ISUOG. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2008        PMID: 18085527     DOI: 10.1002/uog.5224

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  5 in total

1.  The utilization of circulating cell-free fetal DNA testing and decrease in invasive diagnostic procedures: an institutional experience.

Authors:  K E Pettit; A D Hull; L Korty; M C Jones; D H Pretorius
Journal:  J Perinatol       Date:  2014-05-29       Impact factor: 2.521

2.  Long-Term Outcome of Fetuses with Soft Marker and Without Genetic or Structural Abnormality.

Authors:  Migraci Tosun; Emel Kurtoglu Ozdes; Erdal Malatyalioglu; Erhan Yavuz; Handan Celik; Fatma Devran Bildircin; Kubilay Canga; Arif Kokcu; Gonul Ogur
Journal:  J Obstet Gynaecol India       Date:  2018-02-10

3.  Chromosomal microarray analysis for the detection of chromosome abnormalities in fetuses with echogenic intracardiac focus in women without high-risk factors.

Authors:  Min He; Zhu Zhang; Ting Hu; Shanling Liu
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

4.  Performance of Chromosomal Microarray Analysis for Detection of Copy Number Variations in Fetal Echogenic Bowel.

Authors:  Xiangqun Fan; Hailong Huang; Xiyao Lin; Huili Xue; Meiying Cai; Na Lin; Liangpu Xu
Journal:  Risk Manag Healthc Policy       Date:  2021-04-09

5.  Outcome after prenatal diagnosis of fetal urinary tract abnormalities: A tertiary center experience

Authors:  Ayşegül Özel; Ebru Alıcı Davutoğlu; Hakan Erenel; Mehmet Fatih Karslı; Sevim Özge Korkmaz; Rıza Madazlı
Journal:  J Turk Ger Gynecol Assoc       Date:  2018-04-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.